Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:32 pm Sale | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | RA Capital Management, L.P. | 2,866,733 9.400% | -128,290 (-4.28%) | Filing History |
| 2025-02-14 6:31 pm Sale | 2024-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN | RA Capital Management, L.P. | 5,755,577 5.700% | -2,054,275 (-26.30%) | Filing History |
| 2025-02-14 6:31 pm Purchase | 2024-12-31 | 13G | Adagio Medical Holdings, Inc. ADGM | RA Capital Management, L.P. | 1,613,220 9.900% | 275,407 (+20.59%) | Filing History |
| 2025-02-14 6:30 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 4,564,867 9.900% | -533,344 (-10.46%) | Filing History |
| 2025-02-14 6:29 pm Sale | 2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA Capital Management, L.P. | 0 0.000% | -6,809,404 (Position Closed) | Filing History |
| 2025-02-14 6:28 pm Sale | 2024-12-31 | 13G | Cybin Inc. CYBN | RA Capital Management, L.P. | 0 0.000% | -1,529,988 (Position Closed) | Filing History |
| 2025-02-14 6:28 pm Purchase | 2024-12-31 | 13G | CervoMed Inc. CRVO | RA Capital Management, L.P. | 916,063 9.900% | 90,690 (+10.99%) | Filing History |
| 2025-02-14 6:27 pm Sale | 2024-12-31 | 13G | BioAge Labs, Inc. BIOA | RA Capital Management, L.P. | 1,310,589 3.700% | -900,000 (-40.71%) | Filing History |
| 2025-02-14 6:27 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | RA Capital Management, L.P. | 0 0.000% | -1,999,997 (Position Closed) | Filing History |
| 2025-02-14 6:26 pm Sale | 2024-12-31 | 13G | Alto Neuroscience, Inc. ANRO | RA Capital Management, L.P. | 0 0.000% | -2,075,154 (Position Closed) | Filing History |
| 2025-02-14 6:25 pm Purchase | 2024-12-31 | 13G | Monopar Therapeutics Inc. MNPR | RA Capital Management, L.P. | 620,116 9.900% | 108,909 (+21.30%) | Filing History |
| 2025-02-14 6:24 pm Unchanged | 2024-12-31 | 13G | Zura Bio Limited ZURA | RA Capital Management, L.P. | 3,217,503 4.900% | 0 (Unchanged) | Filing History |
| 2025-02-03 5:39 pm Purchase | 2025-01-30 | 13D | 89bio, Inc. ETNB | RA Capital Management, L.P. | 20,013,733 15.100% | 5,759,435 (+40.40%) | Filing History |
| 2024-12-30 6:51 pm Purchase | 2024-12-26 | 13D | Vor Biopharma Inc. VOR | RA Capital Management, L.P. | 39,709,850 31.900% | 16,929,507 (+74.32%) | Filing History |
| 2024-12-06 5:30 pm Purchase | 2024-11-29 | 13G | Alector, Inc. ALEC | RA Capital Management, L.P. | 9,695,228 9.900% | 9,695,228 (New Position) | Filing History |
| 2024-12-05 6:55 pm Purchase | 2024-11-27 | 13G | Kura Oncology, Inc. KURA | RA Capital Management, L.P. | 4,368,998 5.600% | 4,368,998 (New Position) | Filing History |
| 2024-11-26 5:32 pm Purchase | 2024-11-26 | 13D | Cidara Therapeutics, Inc. CDTX | RA Capital Management, L.P. | 1,092,796 9.990% | 389,716 (+55.43%) | Filing History |
| 2024-11-22 4:12 pm Purchase | 2024-11-15 | 13G | Arcellx, Inc. ACLX | RA Capital Management, L.P. | 2,787,327 5.200% | 2,787,327 (New Position) | Filing History |
| 2024-11-18 8:19 pm Unchanged | 2024-11-14 | 13D | 89bio, Inc. ETNB | RA Capital Management, L.P. | 14,254,298 11.900% | 0 (Unchanged) | Filing History |
| 2024-11-15 5:05 pm Sale | 2024-11-13 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 5,098,211 11.000% | -103,934 (-2.00%) | Filing History |